Clinical trialPhase 2 / Phase 3Unknown
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
A Randomized, Double Blinded, Parallel-controlled, Multi-center Phase II/III Study to Compare the Best Support Care (BSC) Plus K-001 Versus BSC Plus Placebo for the Third-line and Later Treatment of Patients With Advanced Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2 / Phase 3
- Status
- Unknown
- Study type
- Interventional
- Start
- 26 September 2017
- Listed end
- March 2021
- Enrollment
- 600 participants
- Sites
- 1
- Primary outcomes
- overall survival
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 12 November 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity. Previously, the phase I study of K001 has shown that K001 was safety and had some effectiveness for pancreatic patients. Now, we would like to lunch a randomized, blinded, parallel-controlled, multi-center phase II/III study to compare the best support care (BSC) plus K-001 versus BSC plus placebo for the third-line and later treatment of patients with advanced pancreatic cancer.